MAP Kinase 2/Erk2, active

N-terminal GST-tagged recombinant, human full length MAP Kinase 2/Erk2, Activated with MEK1 (14-429).

Catalog #: 14-550


Biological Information
Background Information:
MAPK1 (mitogen-activated protein kinase 1, ERK2 or extracellular signal &-regulated protein kinase) is one of the isoforms of MAP kinase. This serine/threonine kinase is activated by dual phosphorylation on tyrosine and threonine residues (Tyr-185 and Thr-183). Phosphorylation of both residues by the upstream activator MEK (mitogen-activated protein Kinase kinase, MAP2K) is essential not only for ERK2 activation, but also for translocation of the ERK2 to the nucleus. Following this activation, ERK2 phosphorylates a large number of regulatory proteins and this directly controls key cellular processes such as transcription, translation and cytoskeletal rearrangement. An inhibitor assay may be of benefit for the treatment of cancer, diabetes, neurodegenerative disorders or asthma. GenBank NM_002745 (amino acid sequence only)
Target Class:
Ser/Thr Kinase; MAPK; ERK subfamily
Accession Number:
NM_002745.4; NM_138957.2
Target Name:
Erk2 (MAPK1)
Target Aliases:
MAPK1, p40, PRKM2, MAPK2, PRKM1, p42-MAPK, p38, p41, ERK, ERK-2, ERT1, P42MAPK, p41mapk, ERK2
Target Species:
Product Type:
Drug Discovery & Development
Storage Conditions:
1 year at -20°C
Usage Disclaimer:
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit for a list of products that are governed by limited use label license terms and relevant patent and trademark information.


14-550x Datasheet

View Document